Physician profile
Nancy Sukys
NPI 1639287774
$2,216.40
in general payments reported to CMS, 2019-2025
14 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $134 · 2021: $458 · 2022: $218 · 2023: $221 · 2024: $412 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $394.59 | 2019-2025 | Freestyle Libre 3, Amplatzer Amulet |
| Astrazeneca Pharmaceuticals LP | $287.07 | 2019-2024 | Airsupra, Lokelma, Breztri |
| Esperion Therapeutics, INC. | $274.91 | 2020-2021 | |
| Edwards Lifesciences Corporation | $205.99 | 2021-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbvie INC. | $196.40 | 2022-2025 | Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $183.28 | 2021-2025 | |
| Amarin Pharma, INC. | $148.99 | 2019-2020 | |
| Amgen INC. | $146.89 | 2019-2024 | Evenity |
| Novo Nordisk INC | $102.74 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $70.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $66.17 | 2021 | |
| Lundbeck LLC | $60.38 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $50.10 | 2019 | |
| Grifols USA, LLC | $28.18 | 2025 | Xembify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Sukys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.